Tratamientos habituales utilizados en cefaleas, neuralgias y SARS-CoV-2. Posicionamiento del grupo de estudio de cefaleas de la Sociedad Española de Neurología
Authors:
- N. MorollónNMN. Morollón
- R. BelvísRBR. Belvís
- A. De DiosADA. De Dios
- N. PagèsNPN. Pagès
- C. González-OriaCGC. González-Oria
- G. LatorreGLG. Latorre
- S. Santos-LasaosaSSS. Santos-Lasaosa
Open Access
- 1 November 2020
- journal article
- research article
- Published by Elsevier in Neurología
- Vol. 35 (9) , 628-632
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?The Lancet Respiratory Medicine, 2020
- Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trialThe Lancet Respiratory Medicine, 2020
- Complicaciones neurológicas por coronavirus y COVID-19Revista De Neurologia, 2020
- Trained immunity in organ transplantationAmerican Journal of Transplantation, 2019
- The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1–7)-Mas axes in pressure overload-induced cardiac remodeling in male miceJournal of Molecular and Cellular Cardiology, 2016
- Ibuprofen Attenuates Cardiac Fibrosis in Streptozotocin-Induced Diabetic RatsCardiology, 2015
- Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive studyThe Lancet Infectious Diseases, 2013
- Mechanisms of Action and Clinical Application of Macrolides as Immunomodulatory MedicationsClinical Microbiology Reviews, 2010
- Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartanAmerican Journal of Physiology-Renal Physiology, 2009
- Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2Circulation, 2005